Background/Aims: The objective of this study is to evaluate the relation between sclerostin, arterial stiffness, and cardiovascular events (CVE) in hemodialysis patients (HD). Methods: Sclerostin level and carotid-femoral pulse wave velocity (PWV) in 97 HD patients and sclerostin level in 40 controls were measured. Results: Sclerostin level was significantly higher in patients than in controls. Sclerostin associated positively with age, male gender, cardiovascular disease, statin use, BMI, and PWV while negatively with alkaline phosphatase, parathormone (PTH), Kt/V, cinacalcet and vitamin D use in univariable correlation analyses. Sclerostin associated positively with male gender and statin use but negatively with PTH in multivariate regression analyses. During observation, 30 fatal or nonfatal CVEs were observed. While univariate correlation analysis showed a positive association between PWV and sclerostin, there was no relation between the two in multivariate regression analysis. Conclusion: Further studies are needed to understand the role of sclerostin in predicting PWV changes in HD patients.

1.
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296–1305.
2.
Ross L, Banerjee D: Cardiovascular complications of chronic kidney disease. Int J Clin Pract 2013; 67: 4–5.
3.
Kumar S, Bogle R, Banerjee D: Why do young people with chronic kidney disease die early? World J Nephrol 2014; 3: 143–155.
4.
Xu T, Xie J, Zong X, Wang W, Ren H, Chen N: Pulse wave velocity: a valuable predictor for cardio-cerebrovascular disease and death in PD patients. Blood Purif 2015; 40: 203–208.
5.
Dahle DO, Eide IA, Asberg A, Leivestad T, Holdaas H, Jenssen TG, Fagerland MW, Pihlstrom H, Mjoen G, Hartmann A: Aortic stiffness in a mortality risk calculator for kidney transplant recipients. Transplantation 2015; 99: 1730–1737.
6.
Tomlinson LA: Methods for assessing arterial stiffness: technical considerations. Curr Opin Nephrol Hypertens 2012; 21: 655–660.
7.
Raggi P, Bellasi A, Ferramosca E, Islam T, Muntner P, Block GA: Association of pulse wave velocity with vascular and valvular calcification in hemodialysis patients. Kidney Int 2007; 71: 802–807.
8.
Nitta K, Akiba T, Suzuki K, Uchida K, Ogawa T, Majima K, Watanabe R, Aoki T, Nihei H: Assessment of coronary artery calcification in hemodialysis patients using multi-detector spiral CT scan. Hypertens Res 2004; 27: 527–533.
9.
Shoji T, Emoto M, Shinohara K, Kakiya R, Tsujimoto Y, Kishimoto H, Ishimura E, Tabata T, Nishizawa Y: Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. J Am Soc Nephrol 2001; 12: 2117–2124.
10.
Pannier B, Guerin AP, Marchais SJ, Safar ME, London GM: Stiffness of capacitive and conduit arteries: prognostic significance for end-stage renal disease patients. Hypertension 2005; 45: 592–596.
11.
Sell DR, Monnier VM: Molecular basis of arterial stiffening: role of glycation – a mini-review. Gerontology 2012; 58: 227–237.
12.
Townsend RR, Wimmer NJ, Chirinos JA, Parsa A, Weir M, Perumal K, Lash JP, Chen J, Steigerwalt SP, Flack J, Go AS, Rafey M, Rahman M, Sheridan A, Gadegbeku CA, Robinson NA, Joffe M: Aortic PWV in chronic kidney disease: a CRIC ancillary study. Am J Hypertens 2010; 23: 282–289.
13.
Kuhl M, Sheldahl LC, Park M, Miller JR, Moon RT: The Wnt/Ca2+ pathway: a new vertebrate Wnt signaling pathway takes shape. Trends Genet 2000; 16: 279–283.
14.
Monroe DG, McGee-Lawrence ME, Oursler MJ, Westendorf JJ: Update on Wnt signaling in bone cell biology and bone disease. Gene 2012; 492: 1–18.
15.
Al-Aly Z, Shao JS, Lai CF, Huang E, Cai J, Behrmann A, Cheng SL, Towler DA: Aortic Msx2-Wnt calcification cascade is regulated by TNF-alpha-dependent signals in diabetic Ldlr-/- mice. Arterioscler Thromb Vasc Biol 2007; 27: 2589–2596.
16.
Shao JS, Cheng SL, Pingsterhaus JM, Charlton-Kachigian N, Loewy AP, Towler DA: Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J Clin Invest 2005; 115: 1210–1220.
17.
Al-Aly Z: Vascular calcification in uremia: what is new and where are we going? Adv Chronic Kidney Dis 2008; 15: 413–419.
18.
Surendran K, Schiavi S, Hruska KA: Wnt-dependent beta-catenin signaling is activated after unilateral ureteral obstruction, and recombinant secreted frizzled-related protein 4 alters the progression of renal fibrosis. J Am Soc Nephrol 2005; 16: 2373–2384.
19.
Cejka D, Jager-Lansky A, Kieweg H, Weber M, Bieglmayer C, Haider DG, Diarra D, Patsch JM, Kainberger F, Bohle B, Haas M: Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Nephrol Dial Transplant 2012; 27: 226–230.
20.
Pelletier S, Dubourg L, Carlier MC, Hadj-Aissa A, Fouque D: The relation between renal function and serum sclerostin in adult patients with CKD. Clin J Am Soc Nephrol 2013; 8: 819–823.
21.
Caira FC, Stock SR, Gleason TG, McGee EC, Huang J, Bonow RO, Spelsberg TC, McCarthy PM, Rahimtoola SH, Rajamannan NM: Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J Am Coll Cardiol 2006; 47: 1707–1712.
22.
Roman-Garcia P, Carrillo-Lopez N, Fernandez-Martin JL, Naves-Diaz M, Ruiz-Torres MP, Cannata-Andia JB: High phosphorus diet induces vascular calcification, a related decrease in bone mass and changes in the aortic gene expression. Bone 2010; 46: 121–128.
23.
Hampson G, Edwards S, Conroy S, Blake GM, Fogelman I, Frost ML: The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women. Bone 2013; 56: 42–47.
24.
Morales-Santana S, Garcia-Fontana B, Garcia-Martin A, Rozas-Moreno P, Garcia-Salcedo JA, Reyes-Garcia R, Munoz-Torres M: Atherosclerotic disease in type 2 diabetes is associated with an increase in sclerostin levels. Diabetes Care 2013; 36: 1667–1674.
25.
Paccou J, Mentaverri R, Renard C, Liabeuf S, Fardellone P, Massy ZA, Brazier M, Kamel S: The relationships between serum sclerostin, bone mineral density, and vascular calcification in rheumatoid arthritis. J Clin Endocrinol Metab 2014; 99: 4740–4748.
26.
Thambiah S, Roplekar R, Manghat P, Fogelman I, Fraser WD, Goldsmith D, Hampson G: Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. Calcif Tissue Int 2012; 90: 473–480.
27.
Brandenburg VM, Kramann R, Koos R, Kruger T, Schurgers L, Muhlenbruch G, Hubner S, Gladziwa U, Drechsler C, Ketteler M: Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study. BMC Nephrol 2013; 14: 219.
28.
Claes KJ, Viaene L, Heye S, Meijers B, d’Haese P, Evenepoel P: Sclerostin: Another vascular calcification inhibitor? J Clin Endocrinol Metab 2013; 98: 3221–3228.
29.
Jin S, Zhu M, Yan J, Fang Y, Lu R, Zhang W, Zhang Q, Lu J, Qi C, Shao X, Zhang H, Jiang R, Ni Z: Serum sclerostin level might be a potential biomarker for arterial stiffness in prevalent hemodialysis patients. Biomark Med 2016; 10: 689–699.
30.
Desjardins L, Liabeuf S, Oliveira RB, Louvet L, Kamel S, Lemke HD, Vanholder R, Choukroun G, Massy ZA: Uremic toxicity and sclerostin in chronic kidney disease patients. Néphrol Thér 2014; 10: 463–470.
31.
Cejka D, Herberth J, Branscum AJ, Fardo DW, Monier-Faugere MC, Diarra D, Haas M, Malluche HH: Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol 2011; 6: 877–882.
32.
Viaene L, Behets GJ, Claes K, Meijers B, Blocki F, Brandenburg V, Evenepoel P, D'Haese PC: Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis? Nephrol Dial Transplant 2013; 28: 3024–3030.
33.
Elias RM, Moysés RM: Serum sclerostin: not only a matter of measurement but also of meaning. Calcif Tissue Int 2016; 98: 642–643.
34.
Modder UI, Hoey KA, Amin S, McCready LK, Achenbach SJ, Riggs BL, Melton LJ 3rd, Khosla S: Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res 2011; 26: 373–379.
35.
Kearns AE, Khosla S, Kostenuik PJ: Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 2008; 29: 155–192.
36.
Kirkpantur A, Balci M, Turkvatan A, Afsar B: Independent association between serum sclerostin levels and carotid artery atherosclerosis in prevalent haemodialysis patients. Clin Kidney J 2015; 8: 737–743.
37.
Cannata-Andia JB, Garcia MR, Alonso CG: Osteoporosis and adynamic bone in chronic kidney disease. J Nephrol 2013; 26: 73–80.
38.
Vervloet MG, Massy ZA, Brandenburg VM, Mazzaferro S, Cozzolino M, Ureña-Torres P, Bover J, Goldsmith D: Bone: a new endocrine organ at the heart of chronic kidney disease and mineral and bone disorders. Lancet Diabetes Endocrinol 2014; 2: 427–436.
39.
Acibucu F, Dokmetas HS, Acibucu DO, Kilicli F, Aydemir M, Cakmak E: Effect of vitamin D treatment on serum sclerostin level. Exp Clin Endocrinol Diabetes 2017; 125: 634–637.
40.
Dawson-Hughes B, Harris SS, Ceglia L, Palermo NJ: Effect of supplemental vitamin D and calcium on serum sclerostin levels. Eur J Endocrinol 2014; 170: 645–650.
41.
Kim KM, Lim S, Moon JH, Jin H, Jung KY, Shin CS, Park KS, Jang HC, Choi SH: Lower uncarboxylated osteocalcin and higher sclerostin levels are significantly associated with coronary artery disease. Bone 2016; 83: 178–183.
42.
Nowak A, Artunc F, SerraA L, Pollock E, Krayenbuhl PA, Muller C, Friedrich B: Sclerostin quo vadis? – is this a useful long-term mortality parameter in prevalent hemodialysis patients? Kidney Blood Press Res 2015; 40: 266–276.
43.
Yang CY, Chang ZF, Chau YP, Chen A, Yang WC, Yang AH, Lee OK: Circulating Wnt/beta-catenin signalling inhibitors and uraemic vascular calcifications. Nephrol Dial Transplant 2015; 30: 1356–1363.
44.
Bruzzese A, Lacquaniti A, Cernaro V, Ricciardi CA, Loddo S, Romeo A, Montalto G, Costantino G, Torre F, Pettinato G, Salamone I, Aloisi C, Santoro D, Buemi M: Sclerostin levels in uremic patients: a link between bone and vascular disease. Ren Fail 2016; 38: 759–764.
45.
Kanbay M, Siriopol D, Saglam M, Kurt Y, Gok M, Cetinkaya H, Karaman M, Unal H, Oguz Y, Sari S, Eyileten T, Goldsmith D, Vural A, Veisa G, Covic A, Yilmaz MI: Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients. J Clin Endocrinol Metab 2014; 99:E1854–E1961.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.